Skip to main content
SIR 2025 Event Main banner
BSCI - Consideration Cases Ad 1
Merit/DPSSME Siege
Back

SIR 2025

Interventional Oncology

Scientific Session

Session: Interventional Oncology - TACE

Is TACE with Atezolizumab-Bevacizumab the Next Step Forward in HCC? Longer Survival Linked to Sequential Systemic Therapy First

Tuesday, April 1, 2025
3:45 PM – 3:54 PM CT
Location: Music City Center, 209 ABC

    Presenting Author(s)

  • Rong Yan, MS

    /
    Zhongda Hospital Affiliated to Southeast University, China (People's Republic)

    • Author/Co-author(s)

  • JL

    Jian Lu, MD

    Deputy Director
    Zhongda Hospital Affiliated to Southeast University, China (People's Republic)

  • HZ

    Hai-Dong Zhu, n/a

    n/a
    Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, China (People's Republic)

  • Gao-Jun Teng, MD, FSIR

    President of the hospital
    Zhong-Da Hospital, Southeast University, China (People's Republic)

Purpose: Combining transarterial chemoembolization (TACE) with systemic therapies such as atezolizumab and bevacizumab(T+A) has shown potential efficacy in patients with unresectable Hepatocellular carcinoma (HCC) This interim analysis aims to evaluate the efficacy and safety of this combination therapy when administered concurrently within a two-month period.

Materials and Methods: This multicenter, real-world study included patients diagnosed with unresectable HCC who received TACE combined with T+A from January 2020 to June 2024, across 37 centers in mainland China. The primary endpoint was overall survival (OS). This trial is registered with ClinicalTrials.gov, NCT06024252.


Results:

Out of a cohort of 335 patients, 293 (259 males) met the inclusion criteria. The interim analysis showed a median OS of 29.97 months and a one-year survival rate of 76.50%. The median PFS was 19.23 months, and the objective response rate (ORR) was 41.6%, with 26 complete responses and 96 partial responses. The disease control rate (DCR) was 84.6%. Common adverse events included bone marrow suppression, decreased white blood cell or platelet counts, among others. Serious adverse events occurred in 9.2% of patients (27/293) and were manageable with standard interventions. Results indicated a longer OS when categorizing the treatment strategies based on whether systemic therapy with T+A was administered first (average OS: 29.94 moths vs,23.58 moths. P < 0.05).



Conclusion: This study is a real-world analysis to highlight the potential benefits of combining TACE with systemic therapy in this patient population. However, longer follow-up is required to better assess both overall survival and the long-term safety profile of this treatment strategy.